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Abstract
Background: Mammalian target of rapamycin (mTOR) complex 1 (mTORC1) acts 
as a downstream effector of phosphatidyl‑inositol‑3 kinase, which is frequently 
hyperactivated in glioblastoma multiforme and links to cell signaling in cellular 
proliferation, differentiation, metabolism, and survival. Although many studies have 
suggested the importance of mTORC1 in tumorigenesis, its role remains unclear 
in brain tumors other than glioblastoma.
Methods: In the present study, we evaluated the activation of mTORC1 in 24 cases 
of primary central nervous system lymphoma (PCNSL).
Results: Immunohistochemical analysis showed overexpression of Rheb, which is 
immediately upstream of mTORC1, in 20 cases of PCNSL. Immunohistochemical 
analysis also showed overexpression of phospho‑4E‑BP1 (Thr37/46) and 
phospho‑S6 (Ser235/236), which are increased after mTORC1 activation as 
mTORC1 downstream effectors in 17 and 21 cases, respectively.
Conclusion: Our data suggest that abnormal activation of the mTORC1 signaling 
pathway may cause tumor growth in patients with PCNSL.
Key Words: mTOR, phospho‑4E‑BP1, phospho‑S6, primary central nervous 
system lymphoma, Rheb
INTRODUCTION
Mammalian target of rapamycin (mTOR) signaling 
impacts most major cellular functions, giving it an 
outsized role in regulating basic cell behaviors such as 
growth and proliferation.[19] Dysregulated mTORC1 
signaling pathway drives tumorigenesis through the 
coordinated phosphorylation of proteins that directly 
regulate protein synthesis, cell‑cycle progression, 
and metabolism, and of transcription factors that 
regulate the expression of genes involved in these 
processes.[30] The mTORC1 signaling pathway is 
inappropriately activated and inhibition of mTORC1 
improves progression‑free survival in patients with 
renal‑cell carcinoma, pancreatic neuroendocrine tumor, 
breast cancer, and lymphangioleiomyomatosis.[3,11,25,38] In 
the brain, abnormally increased activation of mTORC1 
contributes not only to benign tumor diseases such as 
tuberous sclerosis and Lhermitte–Duclos disease but also 
to malignant tumors such as glioblastoma multiforme; 
mTORC1 inhibitors have also been used to reduce the 
volume of subependymal giant‑cell astrocytomas (SEGA) 
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in patients with tuberous sclerosis.[1,6,14,18,20] These suggest 
that mTORC1 inhibitors may be potential alternatives 
to conventional chemotherapies in patients with brain 
tumors in which the mTORC1 signaling pathway is 
abnormally activated, and yet, mTORC1 activation in 
human brain tumors other than gliomas has not been 
well studied.
A small G protein Ras homologue enriched in brain 
(Rheb), regulated by a heterodimer consisting of 
tuberous sclerosis 1 (TSC1) and TSC2, directly 
interacts with mTORC1 and strongly stimulates its 
kinase activity when it is converted into its active 
GTP‑bound state [Figure 1].[19] Overexpression of 
Rheb activates mTORC1, resulting in cell growth, cell 
cycle progression, and tumorigenesis.[23,27,32] Eukaryotic 
translation initiation factor 4E (eIF4E) binding protein 
1 (4E‑BP1) inhibits translation initiation by interfering 
with the interaction between the mRNA cap‑binding 
protein eIF4E and eIF4G1, and consequently blocks 
cell growth and proliferation.[22,33] The phosphorylation 
of 4E‑BP1 by activated mTORC1 prevents its binding 
to eIF4E, enabling it to participate in the formation of 
the eIF4F complex that is required for the initiation of 
cap‑dependent translation [Figure 1].[19] S6, a ribosomal 
protein, is a component of the 40 S ribosomal subunit 
that is phosphorylated by the p70 ribosomal S6 kinases, 
S6K1 and S6K2 [Figure 1]. S6K1 and S6K2 activation 
is directly regulated by mTORC1 [Figure 1]. In diseases 
caused by the hyperactivation of mTORC1, for example, 
SEGA and Lhermitte‑Duclos disease, phosphorylated S6 
(p‑S6) is highly expressed as a downstream effector of 
mTORC1.[1,4,7] Because it is difficult to directly measure 
mTORC1 activity, expression of downstream and/or 
upstream proteins has been measured as an alternative 
method.[19] In particular, p‑S6 expression measured with 
immunohistochemistry or Western blotting tends to 
correlate with mTORC1 activation and appears to be 
associated with tumor sensitivity to mTORC1 inhibitors 
such as rapamycin and its analogs.[5,15,36,37]
Primary central nervous system lymphomas (PCNSL) 
are estimated to account for approximately 3% of 
all CNS tumors. Despite high chemosensitivity and 
radiosensitivity and remissions being frequently 
of short duration, treatment of PCNSL remains 
challenging.[9] Elucidation of activated signaling 
pathways in PCNSL might contribute to better 
understanding of the mechanism of early remissions 
of PCNSL after treatments. In the present study, we 
examined mTORC1 activation in human PCNSLs using 
immunohistochemistry for its upstream and downstream 
markers, Rheb, phospho‑4E‑BP1 (p‑4E‑BP1), and p‑S6. 
Our data demonstrate that the mTORC1 signaling 
pathway is activated in many cases of PCNSL, suggesting 
that abnormal mTORC1 activation may cause growth of 
PCNSL.
MATERIALS AND METHODS
This retrospective study was approved by the Institutional 
Review Boards of Shiga University of Medical Science and 
was performed in accordance with the ethical standards 
laid down in the 1975 Declaration of Helsinki and its 
later amendments.
Tissue samples of consecutive cases of PCNSL (n = 27) 
obtained from January 1, 1998 to March 31, 2015 were 
collected from the surgical pathology files of the Shiga 
University of Medical Science Hospital, Shiga, Japan. 
All samples were obtained during the first surgery before 
chemotherapy and radiotherapy.
Sections of Formalin‑fixed, paraffin‑embedded 
tissues were stained with hematoxylin and eosin. 
Immunohistochemistry was performed for Rheb, which 
is an upstream regulator of mTORC1, and for p‑4E‑BP1 
(Thr37/46) and p‑S6 (Ser235/236), which are downstream 
effectors of mTORC1 [Figure 1] (all antibodies were 
purchased from Cell Signaling Technology, Danvers, 
MA). We performed antigen retrieval with 0.01 M 
citrate buffer (pH 6.0) for 16 min in a microwave 
oven. After peroxidase activity was quenched with 
Figure 1: Schema of upstream and downstream signaling pathways 
of mTORC1. mTORC1 has several upstream pathways. Note 
that Rheb is a direct upstream component and 4E-BP1 and S6 
are downstream components of the mTORC1 signaling pathway. 
GTP-bound Rheb activates mTORC1 and contributes to the 
phosphorylation of 4E-BP1 and S6
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3% hydrogen peroxide in water, biotin and avidin 
binding sites were blocked with Avidin/Biotin Blocking 
Kit (Vector Laboratories, Burlingame, CA) according 
to the manufacturer’s protocol. Primary antibodies 
(Rheb at 1:250, p‑4E‑BP1 at 1:250, p‑S6 at 1:250) were 
diluted in 5% normal goat serum in tris‑buffered saline 
and applied for 24 h at 4°C, followed by biotinylated 
secondary antibodies (Vector) at 1:250 dilution for 2 h 
and avidin‑biotin complex (Elite ABC; Vector) for 1 h at 
room temperature. Diaminobenzidine tetrahydrochloride 
was used as the enzyme substrate to visualize specific 
antibody localization. Slides were counterstained with 
hematoxylin. With having mTORC1 activation at high 
frequency because of TSC inactivation, SEGA were used 
for a positive control.[4] Tissue samples of consecutive 
cases of SEGA (n = 3), which were surgically removed 
from tuberous sclerosis patients because of mass effect 
and/or hydrocephalus, were collected from the surgical 
pathology files of our hospital. This positive control was 
processed concurrently with each tested tumor. For a 
negative antibody control, the tumors were tested without 
the primary antibodies with each tumor. Expressions of 
Rheb, p‑4E‑BP1, and p‑S6 were also evaluated in normal 
human brain (cerebral cortex and cerebral medullary 
substance) tissues (n = 4) and normal human lymph 
node tissues (n = 4), which were autopsy‑derived tissues 
purchased from Capital Bioscience (Gaithersburg, MD), 
ProSci (Poway, CA), US Biomax (Rockville, MD), Alpha 
Diagnostic International (San Antonio, TX), or BioChain 
(Newark, CA).
Immunohistochemical staining quantification was 
categorized into two groups [low expressors, negative 
or focally positive (Figure 2a: Focally positive) in less 
than 25% of tumor cells; high expressors, positive in 
25% (Figure 2b: 25% positive) or more tumor cells] as 
described in previous reports in which ≥25% or ≥20% 
was used as high expression.[1,15] Scoring of staining on 
whole tissue sections was performed by an independent 
observer (AS).
RESULTS
In the normal brain tissues, Rheb was strongly expressed 
in neuronal soma in the cortex as “Ras homologue 
enriched in brain,” and weakly or not expressed in glial 
cells [Figure 3a]. p‑4E‑BP1 was expressed in neither 
neurons nor glial cells [Figure 3b]. p‑S6 was weakly or 
not expressed in neurons, and not expressed in glial cells 
[Figure 3c]. In the normal lymph node tissues, neither 
Rheb nor p‑4E‑BP1 was expressed and p‑S6 was expressed 
in a few lymphocytes [Figure 3d‑f]. In the tissues 
of SEGA, Rheb, p‑4E‑BP1, and p‑S6 were expressed 
moderately in many tumor cells [Figure 3g‑i]. The results 
of the immunohistochemical analysis of Rheb, p‑4E‑BP1, 
and p‑S6 in PCNSLs are shown in Table 1. In three cases, 
Figure 2: Examples of scoring of immunohistochemical staining: 
focally positive (low expresser) (a) and 25% positive (barely high 
expresser) (b). Scale bar = 50 µm in (a)
ba
Figure 3: Rheb (a, d, g), p-4E-BP1 (b, e, h), and p-S6 (c, f, i) 
immunohistochemistry in the normal human cerebral cortex 
(a-c), normal lymph node (d-f), and SEGA (g-i) counterstained with 
hematoxylin. Most of the neuronal somas are strongly Rheb-positive 
in cytoplasm, not p-4E-BP1 positive, and mildly or not p-S6 positive 
(a-c). Glial cells are Rheb- p-4E-BP1-, and p-S6-negative (a-c). In 
normal lymph node, Rheb, p-4E-BP1, or p-S6 is not expressed 
(d-f). In SEGA, Rheb, p-4E-BP1, and p-S6 are moderately expressed 
in tumor cells, suggesting that the mTORC1 signaling pathway is 
activated in these cells. Scale bar = 50 µm in (a)
d
h
c
g
b
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i
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because samples were small and contained less than 
600 tumor cells per section, the result were omitted. All 
PCNSLs are diffuse large B‑cell lymphomas (DLBCL). 
Rheb was highly expressed in 20 cases of PCNSL (n = 24) 
[Figure 4a]. High expression of p‑4E‑BP1 and p‑S6 were 
also observed in 17 cases and 21 cases, respectively 
(n = 24) [Figure 4b and c; Table 1]. In 12 specimens, all 
three mTORC1 activation markers were highly expressed, 
suggesting that mTORC1 had absolutely been activated 
in these specimens [Table 1]. In 7 specimens, Rheb and 
a downstream marker were highly expressed, suggesting 
that mTORC1 had probably been activated [Table 1]. 
However, it remains unclear why only one downstream had 
been highly activated. Three specimens highly expressed 
two downstream markers but not Rheb, suggesting that 
mTORC1 had been activated probably by other upstream 
effector than Rheb [Table 1]. In 1 specimen, only 
p‑4E‑BP1 was highly expressed, suggesting that mTORC1 
might have been activated with activation of neither Rheb 
nor S6K‑S6 signaling pathways [Table 1]. In 1 specimen, 
only Rheb was highly expressed, suggesting that mTORC1 
had not been activated [Table 1]. These results suggest 
that mTORC1 had been highly activated in at least half 
of cases of PCNSL.
DISCUSSION
The present report describes activation of the mTORC1 
signaling pathway in many cases of PCNSL. Both 
proliferation regulator p‑4E‑BP1 and cell size regulator 
p‑S6 were highly expressed in half of cases of PCNSL, 
suggesting that mTORC1 activation contributes to not 
only rapid proliferation but also hypertrophy of the tumor 
cells of PCNSL.[10,29]
Lymphomas and mTORC1
Numerous studies have shown that the mTORC1 
signaling pathway plays important roles in the biology of 
malignant cells, including deregulation of the cell cycle, 
suppression of apoptotic machinery and resistance to 
chemotherapies. The mTORC1 signaling pathway has 
been reported to be activated in systemic lymphomas, 
for example, Hodgkin lymphoma, anaplastic large cell 
lymphoma, diffuse large B‑cell lymphoma, etc.[8] In 
Hodgkin lymphoma, treatment with rapamycin, an 
mTORC1 inhibitor, results in G1‑S cell‑cycle arrest and 
enhances the cytotoxicity of other chemotherapeutic 
agents against Hodgkin/Reed‑Sternberg cells.[17] In 
other lymphomas, rapamycin treatment has also been 
shown to induce G1‑S cell‑cycle arrest and to enhance 
the cytotoxicity of chemotherapeutic agents.[8] PCNSL 
is distributed along the spectrum of systemic DLBCL 
including the activated B‑cell (ABC), the germinal center 
B‑cell (GCB), and the non‑ABC/non‑GCB subtype, 
suggesting that PCNSL possibly shares characteristics, 
for example, hyperactivated signaling pathways, with 
systemic DLBCL.[26] Our results suggest that the 
mTORC1 signaling pathway is activated in not only 
systemic lymphomas but also “primary central nervous 
system” lymphoma and may cause the growth of these 
tumors.
Upstream markers of mTORC1 activation
In the present study, we evaluated mTORC1 activation 
using immunohistochemistry for Rheb, p‑S6, and 
p‑4E‑BP1 because mTORC1 activity cannot be evaluated 
directly. Although many previous reports used expression 
of phospho‑Akt (p‑Akt) (Ser473) as an upstream marker 
of mTORC1 activation, recent studies have shown that 
there are several other upstream pathways of mTORC1, 
for example, mitogen‑activated protein kinase signaling 
pathway, AMP‑activated protein kinase signaling pathway, 
WNT signaling pathway, etc., [Figure 1].[31] It has also 
been reported that mTORC1 activation induces negative 
feedback on PI3K and Akt, and consequently reduces the 
level of p‑Akt.[35] Rheb, the downstream effector of TSC1/
TSC2, directly interacts with mTORC1 and strongly 
stimulates its kinase activity, and its increased expression 
causes mTORC1 activation in some tumors such as 
lymphoma.[19,23,27] Instead of evaluating all upstream 
signaling pathways, we used this proximal activator of 
mTORC1 as an upstream marker of mTORC1 activation 
[Figure 1]. Although GDP‑bound Rheb, into which TSC 
converts GTP‑bound Rheb, provides a less effective 
stimulus to mTORC1 than GTP‑bound Rheb does, 
endogenous Rheb binds preferentially to GTP even under 
basal conditions.[13] Thus, increase in the expression 
Figure 4: Rheb (a), p-4E-BP1 (b), and p-S6 (c) immunohistochemistry 
in PCNSL counterstained with hematoxylin. Most of the tumor cells 
are Rheb-positive in cytoplasm. Furthermore, some of the tumor 
cells are strongly p-4E-BP1 and p-S6 positive, suggesting that the 
mTORC1 signaling pathway is activated in these tumor cells. Scale 
bar = 50 µm in (a)
cba
Table 1: Rheb, p‑4E‑BP1 and p‑S6 expression in PCNSLs
Rheb (+), p‑4E‑BP1 (+), p‑S6 (+) 12
Rheb (+), p‑4E‑BP1 (+), p‑S6 (−) 1
Rheb (+), p‑4E‑BP1 (−), p‑S6 (+) 6
Rheb (−), p‑4E‑BP1 (+), p‑S6 (+) 3
Rheb (−), p‑4E‑BP1 (+), p‑S6 (−) 1
Rheb (+), p‑4E‑BP1 (−), p‑S6 (−) 1
(+): Expressed in 25% or more tumor cells, (−): Expressed in less than 25% tumor cells
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of Rheb has the potential to activate mTORC1 and 
promote tumorigenesis.[21,23,27] In the present study, Rheb 
was highly expressed in 20 cases, in which both p‑4E‑BP1 
and p‑S6 were highly expressed in 12 cases and one of 
them was highly expressed in 7 cases, suggesting that 
overexpression of Rheb may contribute to mTORC1 
activation in PCNSL.
Downstream markers of mTORC1 activation
mTORC1 directly phosphorylates translational regulators 
4E‑BP1 and S6K1, which, in turn, promote protein 
synthesis.[19] The phosphorylation of 4E‑BP1 prevents its 
binding with the cap‑binding protein eIE4, enabling eIF4E 
to participate in the formation of the eIF4F complex and 
resulting in the initiation of cap‑dependent translation.[19] 
Consequently, activated eIF4E preferentially drives the 
translation of mRNA for pro‑tumorigenic genes, including 
cell cycle regulators.[39] In contrast to 4E‑BP1 relating 
with cell proliferation and tumorigenesis, S6 is a 
determinant of cell size, but is not dispensable for cancer 
formation.[10,29] Although S6 is phosphorylated by p‑S6K 
after mTORC1 activation and p‑S6 is commonly used as 
a downstream marker of mTORC1 activation, the exact 
role of p‑S6 in tumorigenesis remains unclear. In the 
present study, p‑4E‑BP1 and p‑S6 were expressed in many 
PCNSL cells, possibly contributing to the proliferation 
and hypertrophy of tumor cells of PCNSL as a result 
of the activation of mTORC1. In some specimens, 
only one downstream pathway was activated [Table 1]. 
Although it remains unclear what mechanisms determine 
selective downstream activation, the activation patterns 
of downstream pathways might predict what drug is 
effective in treatment of each case of PCNSL.
mTORC1 activation in brain tumors
mTORC1 signaling pathway is activated in several 
brain tumors, in particular in gliomas, and increased 
expression of p‑4E‑BP1 and/or p‑S6 in the tumors 
has been reported to correlate with enhancing 
proliferation and low survival.[2,24,28] mTORC1 is also 
activated in pediatric low‑grade glioma and pilocytic 
astrocytoma.[12] In neurofibromatosis‑2 (NF2)‑associated 
meningioma and schwannoma, abnormally activated 
mTORC1 contributes to those aberrant growth and 
proliferation because NF2/Merlin does not work as 
negative regulator of mTORC1 in them.[16] The present 
study showed that mTORC1 is activated in PCNSL, 
suggesting that dysregulated mTORC1 may contribute to 
proliferation and hypertrophy of tumor cells of PCNSL. 
The next question is how we can apply this result to 
clinical practice. Widely used inhibitors of mTORC1 are 
rapamycin and its analogs, however, mTORC1 has been 
reported to have rapamycin‑resistant functions that are 
required for cell growth and proliferation and that are 
mediated by phosphorylation of 4E‑BP1.[34] When we 
take advantage of the abnormal activation of mTORC1 
for the treatment of PCNSL, we should use mTORC1 
inhibitors that can suppress not only S6 but also 4E‑BP1 
phosphorylation, which may contribute to suppress tumor 
cell growth and proliferation and be more effective than 
the treatment with rapamycin and its analogs.
CONCLUSION
The mTORC1 signaling pathway is activated in PCNSL, 
which may contribute to proliferation and hypertrophy of 
tumor cells of PCNSL.
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